Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px

Document › Details

DiaSorin S.p.A.. (7/10/17). "Press Release: DiaSorin Launces Iam CBFB-MYH11, Completing the Diagnostic Test Menu for Molecular Screening of Acute Myeloid Leukemia by Q-LAMP". Saluggia.

	Region	EU (European Union)
	Organisation	DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA)
	Group	DiaSorin (Group)
	Product	Iam CBFB-MYH11 genetic test
	Product 2	Q-LAMP assay
	Person	Eros, Paul (DiaSorin 201607 VP International Marketing for DiaSorin Molecular)
	Person 2	Fava, Riccardo (DiaSorin 201607 IR + Corporate Communications Director)

EARLY DIAGNOSIS WILL AID EFFECTIVE STRATIFICATION OF PATIENT RISK, FACILITATING TIMELY AND EFFECTIVE IMPLEMENTATION OF THERAPY FOR PATIENT MANAGEMENT IMPROVEMENT.

Saluggia (VC) - DiaSorin (FTSE Mid Cap: DIA) launches a new CE-IVD molecular diagnostic test, Iam CBFB-MYH11 (not available in the USA) for the ultra-rapid identification of one of the most common genetic causes of Acute Myeloid Leukemia (AML).

This new test allows reliable, easy and fast 20 minutes detection and simultaneously discrimination of the CBFB-MYH11 type A/D and E fusion transcripts, one of the common aberrations of AML.

Similar to the AML1-ETO, launched in 2016, the CBFB-MYH11 translocation is commonly associated with favorable outcome. Rapid molecular identification of the translocation is therefore crucial for therapeutic decision making. Identification of risk groups in a timely and reliable manner, by genetic means represents in fact a unique opportunity for implementing effective therapy. This is especially important in older patient populations who may not be eligible for bone marrow transplant.

The simultaneous discrimination of the type A/D and E fusion transcripts, moreover, will provide a key information to monitor residual disease during therapy, optimizing patients management.

The Iam CBFB-MYH11, along with the other assays of the DiaSorin portfolio (Iam BCR-ABL, Iam PML-RARA, Iam AML1-ETO), represents the optimal solution for reliable, rapid and simple molecular screening of AML at diagnosis.

Paul Eros, Vice President of International Marketing for DiaSorin Molecular, commented: “With the launch of this assay, after the launch of the Iam AML1-ETO assay, DiaSorin can now provide a complete solution for AML screening, confirming its strong commitment to develop innovative molecular solutions for clinical decision making. The launch of our four Q-LAMP assays in the Italian market has been made possible thanks to a strong collaboration between the most relevant Italian KOLs in the field of hematological malignancy and the molecular development team of DiaSorin”.

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it

Record changed: 2023-06-05